BRISBANE, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that Olerup QTYPE, the fastest real time Human Leukocyte Antigen (HLA) typing diagnostic, has received CE Mark approval and is available on both Roche and Applied Biosystems platforms.

Olerup QTYPE provides tissue typing laboratories with the most suitable product for real time HLA typing of donors and recipients of organ transplants. The workflow is simple and the test is performed within the hour, faster than any other available product on the market. Olerup QTYPE is currently available on both Roche LightCycler^® and Applied Biosystems^® platforms. The mass majority of the real time typing market is covered by these two platforms, giving QTYPE wide market availability.

“We are excited to announce this milestone of broad commercialization of Olerup QTYPE. Between the CE Mark and launch on both PCR platforms, HLA laboratories across the world will have access to the fastest typing solution. With 50% of transplant labs worldwide using Olerup products today, we will continue to utilize our current relationships to provide this innovative solution,” said Peter Maag, CEO at CareDx.

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap^® and AlloSure^® for post-transplant surveillance and Olerup SSP^®, Olerup QTYPE, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding our launch of HeartCare, as well as HeartCare’s prospects. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by us with the SEC on March 22, 2018.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com